LON:FARN Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis GBX 40 -1.00 (-2.44%) As of 04:33 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Faron Pharmaceuticals Oy Stock (LON:FARN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FARN alerts:Sign Up Key Stats Today's Range 40▼ 4250-Day Range 38.70▼ 4852-Week Range 38▼ 240Volume359 shsAverage Volume132,219 shsMarket Capitalization£79.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com Read More Receive FARN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FARN Stock News HeadlinesFaron Pharmaceuticals Grants 2.17 Million Share Options Under 2026 Incentive PlanJuly 1 at 6:10 AM | tipranks.comFaron Registers New Treasury Shares to Support Potential Bond ConversionsJune 11, 2026 | tipranks.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.July 2 at 1:00 AM | Investors Alley (Ad)Several Insiders Invested In Faron Pharmaceuticals Oy Flagging Positive NewsJune 5, 2026 | finance.yahoo.comFaron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary CommitteeJune 5, 2026 | finance.yahoo.comFaron Pharmaceuticals Fined by Nasdaq Helsinki Over Disclosure DelaysJune 5, 2026 | tipranks.comFaron Pharmaceuticals Issues New Shares to Settle Convertible Bond AmortisationsJune 3, 2026 | tipranks.comFaron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of BondsMay 28, 2026 | finance.yahoo.comSee More Headlines FARN Stock Analysis - Frequently Asked Questions How have FARN shares performed this year? Faron Pharmaceuticals Oy's stock was trading at GBX 179 at the start of the year. Since then, FARN stock has decreased by 77.7% and is now trading at GBX 40. How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FARN CIKN/A Webwww.faron.com Phone+358-2-4695151FaxN/AEmployees34Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (22.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£60.23 million Net MarginsN/A Pretax MarginN/A Return on Equity45.13% Return on Assets-70.00% Debt Debt-to-Equity Ratio-133.35 Current Ratio0.84 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 2 per share Price / Cash Flow20.00 Book ValueGBX 1,957.36 per share Price / Book0.02Miscellaneous Outstanding Shares199,515,000Free FloatN/AMarket Cap£79.81 million OptionableNot Optionable Beta1.11 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (LON:FARN) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredGreatest Hedge Fund Manager of All Time: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a histo...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FARN Stock Alerts